Target intelligence / Profile preview

Beta-glucan–bile acid interaction

Molecular classification
Other (Dietary fiber–bile acid physical interaction)
01

Overview

Beta-glucan is a soluble dietary fiber found primarily in oats, barley, and certain mushrooms. When consumed, it forms a viscous gel in the gut that binds bile acids, reducing their reabsorption in the small intestine[1][3][7]. This results in increased excretion of bile acids in feces and compels the liver to convert more cholesterol into bile acids, thereby lowering LDL cholesterol levels in the blood[1][3][5][7]. This mechanism is well established, though "LDL cholesterol absorption/reduction via beta-glucan binding bile acids" is not a single molecular target or receptor but rather describes the overall physiologic effect[3][5][7]. Beta-glucan's cholesterol-lowering efficacy is influenced by its molecular weight, source, and concentration, as well as its impact on gut microbiota and resultant short-chain fatty acid production[2][7].

Other names
Beta-glucan bile acid sequestrationBeta-glucan–mediated cholesterol reductionDietary fiber–bile acid binding
02

Mechanism of action

Physical binding of bile acids by viscous beta-glucan in the gut, impeding their reabsorption[3][7]. Enhanced fecal bile acid excretion requires the liver to synthesize new bile acids from cholesterol, which reduces systemic LDL cholesterol[7]. Increased intestinal viscosity by beta-glucan, decreasing cholesterol and fat absorption[5][8]. Fermentation of beta-glucan by gut microbiota generates short-chain fatty acids, which may also lower cholesterol[1][7].

03

Biological functions

Bile acid sequestrationReduction of cholesterol absorptionPromotion of bile acid excretionModulation of gut microbiota
04

Disease associations

Cardiovascular disease (via modulation of LDL cholesterol[3][7])
05

Safety considerations

Gastrointestinal discomfort (bloating, gas)Possible interference with absorption of fat-soluble vitamins or certain drugs (like other bile acid sequestrants)[3][7]
06

Biomarkers

Serum LDL cholesterol concentrationFecal bile acid content7-alpha-hydroxy-4-cholesten-3-one (marker of bile acid synthesis)[7]

Beyond the preview

Go deeper on Beta-glucan–bile acid interaction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-glucan–bile acid interaction.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call